Table 2.
One-way analyses of factors associated with Toxoplasma gondii seropositivity in 1,857 TORCH-tested patients from Qatar, 2005–2008
| Risk factor | IgM positive* (%) | Odds ratio (95% confidence interval) | IgG positive (%) | Odds ratio (95% confidence interval) |
|---|---|---|---|---|
| Sex | ||||
| Female | 49 (4) | 1.00 | 378 (33) | 1.00 |
| Male | 27 (4) | 0.91 (0.56–1.46) | 194 (28) | 0.79 (0.64–0.97)‡ |
| Age group | < 0.01† | |||
| ≤ 6 mo | 3 (1) | Undefined | 80 (23) | 6.85 (1.63–28.8)§ |
| 7–< 12 mo | 0 (0) | Referent | 2 (4) | 1.00 |
| 1–< 2 yr | 1 (3) | Undefined | 1 (3) | 0.68 (0.06–7.77) |
| 2–10 yr | 1 (1) | Undefined | 6 (8) | 2.06 (0.40–10.7) |
| 11–20 yr | 3 (3) | Undefined | 15 (15) | 4.01 (0.88–18.3)¶ |
| 21–29 yr | 27 (6) | Undefined | 151 (31) | 10.2 (2.45–42.8)§ |
| 30–45 yr | 33 (6) | Undefined | 229 (40) | 15.6 (3.75–64.8)§ |
| > 45 yr | 8 (4) | Undefined | 87 (46) | 19.4 (4.58–82.3)§ |
| Nationality‖ | 0.42† | < 0.01† | ||
| Arabian Peninsula | 28 (4) | 1.00 | 168 (24) | 1.00 |
| African | 15 (5) | 1.27 (0.67–2.41) | 129 (42) | 2.39 (1.79–3.17)§ |
| American continent | 0 (0) | Undefined | 6 (32) | 1.50 (0.56–4.01) |
| Asian | 19 (3) | 0.80 (0.44–1.45) | 182 (30) | 1.41 (1.10–1.80)§ |
| East Medi-terranean/East European | 13 (7) | 1.73 (0.88–3.41) | 79 (40) | 2.16 (1.55–3.02)§ |
| Other/unknown | 1 (6) | 1.53 (0.20–12.0) | 8 (47) | 2.89 (1.10–7.62)‡ |
| Year tested | 0.23† | 0.75† | ||
| 2005 | 27 (5) | 1.00 | 160 (32) | 1.00 |
| 2006 | 17 (4) | 0.78 (0.42–1.45) | 119 (30) | 0.91 (0.68–1.21) |
| 2007 | 19 (4) | 0.69 (0.38–1.26) | 157 (32) | 0.97 (0.74–1.26) |
| 2008 | 13 (3) | 0.50 (0.25–0.98)‡ | 136 (29) | 0.87 (0.66–1.14) |
| CMV-IgG seropositivity | ||||
| No | 4 (4) | 1.00 | 15 (14) | 1.00 |
| Yes | 72 (4) | 1.12 (0.40–3.12) | 557 (32) | 2.90 (1.67–5.05)§ |
| N = 1 missing data | ||||
| CMV-IgM seropositivity | ||||
| No | 76 (4) | 1.00 | 550 (31) | 1.00 |
| Yes | 0 (0) | Undefined | 22 (34) | 1.15 (0.68–1.95) |
| N = 1 missing data | ||||
| Rubella IgG seropositivity | ||||
| No | 27 (5) | 1.00 | 199 (34) | 1.00 |
| Yes | 49 (4) | 0.84 (0.52–1.36) | 373 (29) | 0.82 (0.67–1.01)¶ |
| HSV-1 IgG seropositivity | ||||
| No | 20 (3) | 1.00 | 177 (25) | 1.00 |
| Yes | 56 (5) | 1.73 (1.03–2.90)‡ | 395 (34) | 1.53 (1.24–1.89)§ |
| HSV-1 IgM seropositivity | ||||
| No | 76 (4) | 1.00 | 566 (31) | 1.00 |
| Yes | 0 (0) | Undefined | 6 (38) | 1.35 (0.49–3.74) |
| HSV-2 IgG seropositivity | ||||
| No | 62 (4) | 1.00 | 433 (31) | 1.00 |
| Yes | 14 (3) | 0.68 (0.38–1.23) | 139 (30) | 0.98 (0.78–1.23) |
| HSV-2 IgM seropositivity | ||||
| No | 65 (4) | 1.00 | 527 (30) | 1.00 |
| Yes | 11 (11) | 3.03 (1.55–5.94)§ | 45 (43) | 1.74 (1.17–2.60)§ |
*
Three patients missing IgM results were excluded.
†
Global P value.
‡
P < 0.05
§
P < 0.01
¶
0.05 < P < 0.10
‖
Defined in Materials and Methods.